Merck begins tender offer to acquire Idenix
WHITEHOUSE STATION, N.J. — Merck announced on Friday that it is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals. On June 9, Merck announced its intent to acquire Idenix.
Upon the closing of the tender offer, stockholders of Idenix will receive $24.50 in cash for each share of Idenix common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Idenix will become a wholly owned subsidiary of Merck.
Merck will file Friday with the Securities and Exchange Commission a tender offer statement on Schedule TO, which provides the terms of the tender offer. In addition, Idenix will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of the Idenix board of directors that Idenix stockholders accept the tender offer and tender their shares.
The tender offer will expire at 5 pm EDT on Aug. 4, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to customary terms and conditions, including the tender of a number of shares which, together with shares then owned by Merck (if any), represents a majority of the outstanding shares, and the expiration or the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Teva reaches settlement in ProAir HFA patent case
JERUSALEM — Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.
This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016 and lasting until June 2018, when the limits will no longer apply.
There are currently no additional challenges to the IP for ProAir HFA and no further litigation pending. Teva stated that it will continue to “vigorously” defend its intellectual property rights relating to its products.
Walgreens offering whooping cough vaccinations in California pharmacy locations
DEERFIELD, Ill. — Walgreens has announced that it is now offering vaccinations that provide protection against pertussis (whooping cough) at all of its more than 600 stores throughout the California, as the California Department of Public Health is urging vaccination with the state reaching epidemic levels of reported whooping cough cases.
Vaccinations are available daily during all pharmacy hours with no appointment necessary and are covered by most insurance plans.
“We support the recommendations of health officials and stress that vaccination is the best protection people can get from whooping cough,” stated Sepi Soleimanpour, California market pharmacy director for Walgreens. “Walgreens pharmacists continue to play an important role in providing more convenient access to vaccinations and other preventive services to help Californians get, stay and live well.”
Walgreens pharmacists in California can administer immunizations to anyone age 10 and older.
The CDPH recommends the tetanus, diphtheria, pertussis (Tdap) vaccine for the following groups:
- Pregnant women and infants 6 weeks and older;
- All adults who provide care to infants and adults living in a household with an infant, including adults age 65 and older; and
- Preadolescents (ages 7 to 10 years) who are not up to date on pertussis vaccinations and who are living in a household with an infant.
According to the Centers for Disease Control and Prevention, whooping cough is a highly contagious respiratory tract infection primarily affecting young children. Teens and adults whose immunity has faded are also at risk. CDPH says there have been more than 3,400 whooping cough cases reported in 2014, well ahead of the number of cases reported all of last year. There have been more than 800 cases reported in the last two weeks alone.